Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 7/20 | 0.52 |
| ▸ | KIT | P10721 | 4/20 | 0.51 |
| ▸ | FLT3 | P36888 | 3/20 | 0.51 |
| ▸ | ABL1 | P00519 | 12/20 | 0.49 |
| ▸ | SIK2 | Q9H0K1 | 12/20 | 0.49 |
| ▸ | SIK3 | Q9Y2K2 | 12/20 | 0.49 |
| ▸ | SIK1 | P57059 | 10/20 | 0.49 |
| ▸ | PKMYT1 | Q99640 | 3/20 | 0.47 |
| ▸ | LYN | P07948 | 3/20 | 0.46 |
| ▸ | BTK | Q06187 | 2/20 | 0.46 |
| ▸ | EPHB6 | O15197 | 2/20 | 0.45 |
| ▸ | EGFR | P00533 | 2/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | FYN | P06241 | 2/20 | 0.45 |
| ▸ | CSF1R | P07333 | 2/20 | 0.45 |
| ▸ | YES1 | P07947 | 2/20 | 0.45 |
| ▸ | RET | P07949 | 2/20 | 0.45 |
| ▸ | HCK | P08631 | 2/20 | 0.45 |
| ▸ | BCR | P11274 | 2/20 | 0.45 |
| ▸ | BRAF | P15056 | 2/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21952671 | 0.84 | SRC (0.53) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL17469517 | 0.84 | SRC (0.53) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL16809275 | 0.83 | SRC (0.56) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL13532034 | 0.80 | KIT (0.47) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL24122681 | 0.80 | SRC (0.53) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL19928686 | 0.80 | SRC (0.56) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL30011158 | 0.78 | HRH4 (0.51) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL793547 | 0.78 | HRH4 (0.51) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL11981518 | 0.77 | SORD (0.57) | SRCKITFLT3ABL1SIK2 | |
| SCHEMBL19928666 | 0.77 | SRC (0.53) | SRCKITFLT3ABL1SIK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | CERBIOS-PHARMA SA (CH) | 2015-09-17 | — | — | US | disclosed |
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | CERBIOS-PHARMA SA (CH) | 2015-09-17 | — | — | US | disclosed |
| EP-2918584-A1 | Process and intermediates for the preparation of dasatinib | Cerbios-Pharma S.A. (CH) | 2015-09-16 | — | — | EP | disclosed |
| US-9115124-B1 | Process and intermediates for the preparation of dasatinib | CERBIOS-PHARMA SA (CH) | 2015-08-25 | — | — | US | disclosed |
| US-9115124-B1 | Process and intermediates for the preparation of dasatinib | CERBIOS-PHARMA SA (CH) | 2015-08-25 | — | — | US | disclosed |
| US-20130095100-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-20130095100-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8338425-B2 | Heterocyclic kinase inhibitors | CONCERT PHARMACEUTICALS, INC. (US) | 2012-12-25 | — | — | US | disclosed |
| EP-2222166-B9 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC (US) | 2012-11-07 | — | — | EP | disclosed |
| EP-2222166-B1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC (US) | 2012-06-27 | — | — | EP | disclosed |
| WO-2009076373-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC. (US) | 2009-06-18 | — | — | WO | disclosed |
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | CONCERT PHARMACEUTICALS INC. (US) | 2009-06-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150259337-A1 | PROCESS AND INTERMEDIATES FOR THE PREPARATION OF DASATINIB | ABL1, SRC, ABL2 | SRC 2/4885KIT 792/4885FLT3 19/4885 |
| US-20090149399-A1 | HETEROCYCLIC KINASE INHIBITORS | ABL1, ABL2, SRC | SRC 3/4885KIT 510/4885FLT3 11/4885 |
| US-20130095100-A1 | HETEROCYCLIC KINASE INHIBITORS | ABL1, ABL2, SRC | SRC 3/4885KIT 510/4885FLT3 11/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.